Vancomycin-induced Henoch-Schönlein purpura: a case report
© Bataille et al; licensee BioMed Central Ltd. 2012
Received: 24 October 2011
Accepted: 10 April 2012
Published: 10 April 2012
Henoch-Schönlein purpura is a small-vessel systemic vasculitis. Although its exact pathophysiology remains unknown, Henoch-Schönlein purpura has been reported in association with various medical conditions including hypersensitivity. We report the case of a patient with vancomycin-induced Henoch-Schönlein purpura.
A 42-year-old Caucasian man who had previously undergone a heart transplant was diagnosed as having an intra-abdominal abscess after he underwent a Hartmann procedure. At 15 days after initiation of antibiotic therapy including vancomycin, he developed a purpuric rash of the lower limbs, arthralgia, and macroscopic hematuria. At that time, our patient was already on hemodialysis for end-stage renal disease. Henoch-Schönlein purpura was diagnosed. After a second 15-day course of vancomycin, a second flare of Henoch-Schönlein purpura occurred. Skin biopsies showed leucocytoclastic vasculitis with IgA deposits and eosinophils in the peri-capillary inflammatory infiltrate, suggesting an allergic mechanism. After vancomycin was stopped, we did not observe any further flares. Only five cases of isolated cutaneous vasculitis, one case of lupus-like syndrome and one case of Henoch-Schönlein purpura after vancomycin treatment have been described to date in the literature.
Clinicians should be aware that systemic vasculitis can be induced by some treatments. Vancomycin is a widely prescribed antibiotic. Occurrence of rare but serious Henoch-Schönlein purpura associated with vancomycin requires its prompt discontinuation.
Henoch-Schönlein purpura (HSP) is a small-vessel systemic vasculitis. Its usual clinical presentation includes vascular purpura, abdominal pain, arthralgia, and glomerulonephritis. Although its exact pathophysiology remains unknown, HSP has been reported in association with various medical conditions such as cancer, blunt trauma, monoclonal IgA gammopathy, as well as in patients with Wiskott-Aldrich syndrome, chronic alcoholic liver disease, or α1-anti-trypsin deficiency . HSP has also been described in association with hypersensitivity. Several drugs, such as ciprofloxacin, acetylsalicylic acid, carbidopa/levodopa, cocaine, acetyl cholinesterase inhibitors, carbamazepine and streptokinase have been involved in the induction of HSP . Here, we report what is to the best of our knowledge only the second case of vancomycin-induced HSP.
A 42-year-old Caucasian man was referred to our Nephrology Department. He presented with acute renal failure linked to severe dehydration secondary to diarrhea that had lasted a week. He was known to have end-stage renal disease secondary to nephrotoxicity from calcineurin inhibitors administered over 15 years as part of his heart transplant anti-graft rejection regimen, but had not started hemodialysis yet. His estimated glomerular filtration rate (GFR), using Modification of Diet in Renal Disease (MDRD) calculation, was 16.8 mL/minute/1.73 m2 before admission, and he had only mild proteinuria (0.56 g/24 hours) and no hematuria.
On admission, his clinical and specifically his abdominal examinations were unremarkable except for the presence of non-hemorrhagic and non-mucoid diarrhea associated with fever. Community-acquired infectious gastroenteritis was suspected. Our patient's medical history revealed he had been diagnosed as having a transposition of the great arteries that led to an initially successful heart transplantation 15 years ago, before the occurrence of chronic cardiac transplant rejection. As a former smoker, he had also had an isolated ischemic stroke five years ago, but had no history of allergies or anaphylaxis. A recent echocardiograph showed congestive heart failure, with, a left ventricular ejection fraction of 30% and pulmonary hypertension. His immunosuppressive regimen included cyclosporin (45 mg twice a day) and prednisone (5 mg/day). He was given intravenous antibiotic therapy including ceftriaxone (1 g/day) and oral ciprofloxacin (500 mg/day).
By day 24 after admission, our patient showed clinical improvement. He had no further fever or diarrhea, and his biological test results had normalized, so piperacillin/tazobactam was stopped. On day 27, his fever recurred. A second abdominal CT scan showed an abdominal peri-hepatic abscess, and antibiotic therapy was restarted (piperacillin/tazobactam (4 g twice a day), gentamycin (a single injection), and vancomycin (one injection at each hemodialysis session). By day 36, our patient became afebrile and a third CT scan showed regression of the peri-hepatic fluid collection. Antibiotic therapy was again stopped on day 41, after a second 15-day course.
On day 53 after admission, that is, 12 days after the first eruption occurred and after antibiotic therapy was restarted, our patient presented with arthritis of the right knee and left elbow. Arthritis regressed spontaneously within 48 hours, and no articular puncture was performed.
On day 58 after admission, he then presented with a second purpuric eruption of both legs, associated with arthralgia and macroscopic hematuria. All bacteriological and viral test results were negative and he was still receiving antibiotics at that time, so that antibacterial therapy was interrupted. A full-body CT scan showed no more abscess and no adenopathy, but ascitis, which on puncture produced a sterile fluid. A second skin biopsy was performed on the day the purpura appeared. It showed the same leucocytoclastic dermal vasculitis with eosinophils, but vascular IgA and C3 deposits were found with immunofluorescence imaging (Figure 3).
After antibiotic therapy was stopped, our patient finally recovered entirely with disappearance of purpura, arthritis and hematuria, and has not relapsed after a follow-up period of eight months.
HSP is a small-vessel systemic vasculitis characterized by vascular wall deposits of immune complexes containing mainly IgA. It can affect the skin, gut, and glomeruli vessels, and is often associated with purpura, abdominal pain, hematuria, and arthralgia or arthritis . HSP is the most common vasculitis in childhood, but can also occur in adults .
Diagnostic criteria for HSP in children have been recently validated as an association between the presence of purpura in a lower limb plus one of the following four criteria: (1) abdominal pain, (2) histopathology (that is, IgA), (3) arthritis or arthralgia, and (4) renal involvement .
In our patient, concomitant occurrence of purpuric lesions, arthritis, macroscopic hematuria, and an exhaustive immunological exploration with negative results confirmed the diagnosis of HSP. Consistent with this diagnosis, his plasmatic IgA dosage was elevated.
A very surprising finding was the involvement of the kidney in our patient with end-stage renal disease. The chronology was clearly suggestive of HSP, with, macroscopic hematuria occurring concomitantly to each new purpuric eruption, and disappearing within a few days. However, as he was already under hemodialysis, we were not able to fully evaluate the severity of the renal involvement of the vasculitis in our patient.
In our patient, the first skin biopsy, performed several days after the purpuric eruption, showed leucocytoclastic vasculitis and IgM deposits (by immunofluorescence) (Figure 3). Specific leucocytoclastic vasculitis of the skin is a main symptom of HSP . It is classically associated with IgA deposits, but might also be associated, as in our patient, with IgM deposits, especially when a biopsy is performed later, and when the kidney is involved . Indeed, the second biopsy, performed shortly after the eruption, showed IgA deposits (by immunofluorescence), which confirmed HSP. Consistent with an allergic mechanism, optical microscopy showed the presence of eosinophilic polynuclear cells in the inflammatory infiltrate.
The pathophysiology of HSP has not been totally elucidated, but may be related to the production of abnormally glycosylated IgA, which is not sufficiently cleared by the liver and leads to the formation of IgA macromolecules that accumulate in the circulation, and subsequently become deposited in the vessel walls causing vasculitis . Most cases of HSP are primary, but some episodes can be related to an identified etiology, such as infection, medication , or neoplasia .
Our patient had no history of HSP. Thus, it was probably secondary to his recent medical condition. An infectious cause was unlikely as our patient had no fever at the time of the first cutaneous eruption; no bacterial, fungal or viral infection was found, although extensive explorations were made, and the purpuric eruption relapsed while our patient was receiving an antibiotic therapy and the intra-abdominal abscess was well controlled on the CT scans. Further, purpura appeared after antibiotic therapy initiation and disappeared after antibiotic therapy withdrawal. Finally, eosinophils were found in skin biopsies.
From the literature, drugs that have already been associated with HSP are clarithromycin, carbidopa, cytarabine, enalapril/lisinopril, ciprofloxacin, acetylsalicylic acid, cocaine, acetyl cholinesterase inhibitors, carbamazepine, and streptokinase .
In our patient's case, the evolution of HSP was strongly linked with vancomycin: both attacks occurred about 15 days after vancomycin treatment was started, and after vancomycin was stopped the evolution of HSP stopped and our patient was cleared of HSP. In the literature, vancomycin-induced vasculitis has been reported to occur from 1 to 27 days after the start of vancomycin therapy [4–9].
According to a French causality assessment method for unexpected or toxic effects of drugs , chronological evolution is very suggestive (first attack 16 days after treatment with vancomycin was started, aggravation after reintroduction, and then regression of symptoms with no more HSP attacks after vancomycin was stopped) when there is no evidence of other possible etiologies.
Several cases of vasculitis following vancomycin treatment have been reported in the literature: five cases of isolated leucocytoclastic cutaneous vasculitis [5–8] and one case of lupus-like syndrome . To the best of our knowledge, only one case of HSP linked to vancomycin has been described previously . In that case, a patient treated with vancomycin with a staphylococcal chest infection presented with HSP and histologically proven acute interstitial nephritis. As he had preserved renal function, the interstitial nephritis was associated with oliguric acute renal failure. The authors hypothesized that either an anaphylactic reaction or a staphylococcal glycoprotein release had initiated HSP.
No other cases were found in the French Pharmacovigilence database using the keywords HSP, vancomycin, or teicoplanin. Interestingly, Marshall et al. reported induced vasculitis cross-reactivity between teicoplanin and vancomycin .
We report only the second case of vancomycin-induced Henoch-Schönlein purpura that involved the skin, joints, and kidneys. Diagnosis was made possible by the combination of specific clinical and histological findings, and in particular the timing of events with regard to the introduction and withdrawal of glycopeptides. This is a rare, maybe under-diagnosed, but serious adverse event that needs to be considered and if suspected, should lead to prompt discontinuation of glycopeptides.
This case has been registered as French Pharmacovigilence case no. MA20110866; Base Nationale de Pharmacovigilance.
Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Davin JC, Weening JJ: Henoch-Schönlein purpura nephritis: an update. Eur J Pediatr. 2001, 160: 689-695.View ArticlePubMedGoogle Scholar
- Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M: Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010, 69: 798-806. 10.1136/ard.2009.116657.View ArticlePubMedGoogle Scholar
- Takeuchi S, Soma Y, Kawakami T: IgM in lesional skin of adults with Henoch-Schönlein purpura is an indication of renal involvement. J Am Acad Dermatol. 2010, 63: 1026-1029. 10.1016/j.jaad.2009.11.690.View ArticlePubMedGoogle Scholar
- Michail S, Vaiopoulos G, Nakopoulou L, Revenas C, Aroni K, Karam P, Stathakis C, Thosios T: Henoch-Schoenlein purpura and acute interstitial nephritis after intravenous vancomycin administration in a patient with a staphylococcal infection. Scand J Rheumatol. 1998, 27: 233-235. 10.1080/030097498440886.View ArticlePubMedGoogle Scholar
- Heijnen EB, Bentala M, van der Meer NJ: Purpura in a patient receiving vancomycin: a leukoclastic vasculitis?. J Cardiothorac Vasc Anesth. 2011, 25: 390-391. 10.1053/j.jvca.2010.02.027.View ArticlePubMedGoogle Scholar
- Felix-Getzik E, Sylvia LM: Vancomycin-induced leukocytoclastic vasculitis. Pharmacotherapy. 2009, 29: 846-851. 10.1592/phco.29.7.846.View ArticlePubMedGoogle Scholar
- Marshall C, Street A, Galbraith K: Glycopeptide-induced vasculitis: cross-reactivity between vancomycin and teicoplanin. J Infect. 1998, 37: 82-83. 10.1016/S0163-4453(98)91077-5.View ArticlePubMedGoogle Scholar
- Rawlinson WD, George CR: Vancomycin-induced vasculitis. Med J Aust. 1987, 147: 470-PubMedGoogle Scholar
- Markman M, Lim HW, Bluestein HG: Vancomycin-induced vasculitis. South Med J. 1986, 79: 382-383. 10.1097/00007611-198603000-00033.View ArticlePubMedGoogle Scholar
- Bégaud B, Evreux JC, Jouglard J, Lagier G: Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985, 40: 111-118.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.